A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a mojor histocompatibility comples on an antigen presenting cell, and wherein said B chain is capable of binding wiht a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include and Y chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include and A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptpr moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue. Advantageously, the movel peptide sequence is capable of shifting a type-1 immune response to a type-2 immune response or from a type-2 immune response to a type-1 immune response.

Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administration of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP(35-58) had no effect on (F) or (B) anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of (F) and (B) CSF anti-MBP levels. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between Pro86 and Pro95.

The present invention is directed to antixoidant peptides produced by the proteolytic digestion of soy protein isolate. These peptides may be purified and used in either pharmaceutical or dietary compositions.

It is intended to provide a novel receptor of LPA and a method of screening a drug such as an LPA receptor antagonist using the same. Use as a lysophosphatidic acid (LPA) receptor comprising a G protein-coupled protein p2y9. More specifically, use of the G protein-coupled protein p2y9 as a lysophosphatidic acid (LPA) receptor. A method of screening an agonist or an antagonist to the LPA receptor as described above by using the receptor.

A binding molecule comprising a support structure of at least one cyclic molecular subunit and at least two side chain subunits, where the side chain subunits are polypeptide chains containing natural and/or unnatural D- and/or L-amino acids and/or polynucleotide chains, and are covalently bonded to the support structure, is new. Independent claims are also included for: (1) preparing the binding molecule using solid phase synthesis, where the method comprises binding the peptide of the side chain subunit to the solid phase, extending the amino acids and optionally coupling to the support structure; (2) peptide of sequence (Ia) or (Ib), where the side chain subunits have sequence homology of at least 80 %; and (3) a pharmaceutical comprising the binding molecule and/or peptide. Ala-Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-T1-Gln-Leu-Gln-Leu-Glu-His-X1-X2-X3-X4-X5-Gln-Met-Ile-Leu-Asn-Gly-Ile-Asn-Asn (Ia); Thr-Ile-Val-X6-Phe-Leu-Asn-Arg-Trp-Ile-Thr-Phe-X7-Gln-Ser-X8-Ile-Ser-Thr-Leu-T1 (Ib). X1 and X2 = Ile or Leu; X3 = Val, Leu or Met; X4 = Glu, Asp or Lys; X5 = Leu or Phe; X6 = Glu or Asp; X7 = Ala, Gly or Cys; X8 = Ala or Ile; and T1 = Thr.

The present invention relates to pharmaceutical compositions based on antiinflammatory active ingredients and to the use thereof for the treatment of rheumatoid diseases. The compositions comprise lactalbumin hydrolysate or a fraction thereof. Substantially lower doses of the antiinflammatory drugs are thus possible than is conventionally necessary to achieve a particular antiinflammatory effect.

Chemical patent from PubChem database. Patent Number: AT-E399536-T1. Title: Novel Pharmaceutical Composition. Filing Date: 2005-01-20. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: The present invention relates to a novel pharmaceutical composition comprising one or more active pharmaceutical ingredients and pharmaceutically acce... IPC Classifications: C07C, C07B, A61K. This patent covers 15 claims related to 5 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

The invention relates to novel citrulline peptides derived from fibrin α and β chains which are recognizable by specific citrulline antiprotein autoantibodies (AAPC) of a rheumatoid arthritis (PR) and to the use thereof for detecting the presence of said specific PR AAPC in a biological sample.

A method is provided for increasing the specific activity of a type III antifreeze protein when said protein is prepared by expression in a heterologous fungal species of a gene encoding the protein sequence, by means of reducing the extent of glycosylation of the protein.

Chemical patent from PubChem database. Patent Number: AT-E399765-T1. Title: Process for Preparing Therapeutic Agents. Filing Date: 2012-03-22. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: A process for preparing therapeutic agents is described, involving multiple synthetic steps with optimized reaction conditions. The process enables la... IPC Classifications: A61K, A61P, C07D. This patent covers 23 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.